DAX23.564 +0,5%Est505.739 +0,4%MSCI World4.343 -0,1%Top 10 Crypto9,7600 -0,5%Nas22.374 +1,2%Bitcoin64.480 -0,8%Euro1,1472 -0,3%Öl104,6 +3,6%Gold5.009 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Commerzbank CBK100 Siemens Energy ENER6Y NVIDIA 918422 BYD A0M4W9 Lufthansa 823212 Deutsche Telekom 555750 DroneShield A2DMAA SAP 716460 Bayer BAY001 Volkswagen (VW) vz. 766403 Deutsche Bank 514000 Allianz 840400 TUI TUAG50 Shell (ex Royal Dutch Shell) A3C99G
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Asiens Börsen mehrheitlich im Plus
Top News
Bilanzen & Termine: Tesla, NVIDIA, Apple, Amazon & Co. - Ergebnisse der Tech-Riesen in der aktuellen Saison Bilanzen & Termine: Tesla, NVIDIA, Apple, Amazon & Co. - Ergebnisse der Tech-Riesen in der aktuellen Saison
Ausblick: HelloFresh präsentiert Bilanzzahlen zum jüngsten Jahresviertel Ausblick: HelloFresh präsentiert Bilanzzahlen zum jüngsten Jahresviertel
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Renditechancen in Schwellenländern entdecken - mit ETFs von Amundi einfach und günstig investieren.
Wer­bung

Sanofi Aktie

Kaufen
Verkaufen
Sanofi Aktien-Sparplan
38,40 EUR +0,20 EUR +0,52 %
STU
43,99 USD +0,40 USD +0,92 %
BTT
finanzen.net zero
Sanofi jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
KGV20,14
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN662283

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS80105N1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNY

Sanofi Aktien News

DatumMeistgelesen
PR NewswireCIBC launches additional European Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC launches additional European Canadian Depositary Receipts ("CDRs")
PR Newswire/C O R R E C T I O N -- Sanofi-Aventis Canada Inc./
Wer­bungSanofi-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR Newswire/C O R R E C T I O N -- Sanofi-Aventis Canada Inc./
PR NewswireSanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
PR NewswireSanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
PR NewswireEVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
PR NewswireSanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
PR NewswireNew Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
PR NewswireBEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
PR NewswireSanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
GlobeNewswirePress Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - May 2025
PR NewswireSanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care
GlobeNewswirePress Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
GlobeNewswirePress release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
GlobeNewswirePress Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
GlobeNewswirePress Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
PR NewswireSanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
GlobeNewswirePress Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
GlobeNewswirePress Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
GlobeNewswirePress Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
GlobeNewswirePress Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
GlobeNewswirePress Release: Sanofi completes acquisition of DR-0201
PR NewswireSanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
GlobeNewswirePress Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - April 2025
PR NewswireSanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - March 2025
GlobeNewswirePress Release: Annual General Meeting of April 30, 2025

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.